Our first product and lead platform technology is AVERSA, and abuse deterrent tech which we believe to be applicable to any patch on the market today.

AVERSA™ Fentanyl Abuse Deterrent

Indication

AVERSA™ Transdermal Technology

Chronic Pain

Pre-Clinical Phase 1 FDA Filing

AVERSA™ Buprenorphine Abuse Deterrent

Indication

AVERSA™ Transdermal Technology

Chronic Pain

Pre-Clinical Phase 1 FDA Filing

AVERSA™ Methylphenidate

Indication

AVERSA™ Transdermal Technology

Attention Deficit Hyperactivity Disorder (ADHD)

Pre-Clinical Phase 1 FDA Filing

4P Exenatide​

Indication

Novel Transdermal

Type 2 Diabetes

Pre-Clinical Phase 1 FDA Filing

4P FSH

Indication

Novel Transdermal

Infertility

Aversa™ abuse deterrent technology can be incorporated into any transdermal patch that has a risk of abuse.

Get in touch

To find out more, or to enquire about our partnership options, please contact our team who can help find the right solution for your business.